GlaxoSmithKline ( GSK ) recently presented positive data on its oncology drug, Votrient (pazopanib) from a pivotal phase III study. The phase III study COMPARZ (COMParing the efficacy,
See more here:
Encouraging Data on Glaxo’s Drug – Analyst Blog
GlaxoSmithKline ( GSK ) recently presented positive data on its oncology drug, Votrient (pazopanib) from a pivotal phase III study. The phase III study COMPARZ (COMParing the efficacy,
See more here:
Encouraging Data on Glaxo’s Drug – Analyst Blog